

## Nephrology and clinical chemistry: friends for life!

Renal diseases are frequently *pauci*- or asymptomatic. It is not rare that patients with end-stage chronic kidney disease (CKD) or severe acute kidney injury (AKI) are admitted to the emergencies with only recent symptoms, even if, in case of CKD, the pathophysiological process is ongoing for months or years. In this context, one can only underline the fundamental importance of the clinical laboratory to diagnose CKD or AKI. Both blood and urine analyses are of paramount importance to detect, as early as possible, kidney injuries with the objective of preventing and treating kidney diseases. Both guidelines on AKI and CKD management propose definitions for AKI and CKD (1,2). In these situations, serum creatinine remains the mostly used biomarker to estimate renal function. However, serum creatinine is far from perfect both from a clinical and laboratory points of view (3,4). Bargnoux and colleagues extensively reviewed all limitations of serum creatinine. Among these limitations, numerous analytical interferences have been described (5). Also, in the current era of equations to estimate glomerular filtration (GFR), the standardization of serum creatinine takes a long time but is mandatory (6). For both aspects (standardization and interferences), the added value of enzymatic assays needs to be emphasized (6,7). For AKI diagnosis, Makris summarized the apparently simple recommendations, but then, reviewed into details all the difficulties in applying the AKI criteria, especially serum creatinine changes and urine output (2). Ebert and Schaeffner summarized the current creatinine-based equations used to GFR rate. Then, they discuss in their review the potential role for other renal biomarkers. Cystatin C is certainly the most studied until now (8-10), but other avenues of research exist, such as beta-trace protein (11,12) or panel of biomarkers proposed with a metabolomic approach (13). Classical creatinine- and new biomarkers-based equations still remain estimation of GFR, and they all share, more or less, the same degree of imprecision (4,14). In specific situations and/or in specific subjects, a highly precise method is required to measure (not estimate) GFR (15,16). Once again, the clinical laboratory plays a key role in the development of reference methods to measure GFR. Indeed, today, the most frequently used method is the plasma clearance of iothexol. Carrara and Gaspari extensively reviewed this method, insisting both on analytic strengths and safety. Measuring GFR, as a reference method, is probably underused in Nephrology whereas it is an easy and relatively cheap method (16,17). CKD is associated with non-renal complications such as anemia, acidosis and/or hyperkalemia (18). Among these complications, bone disorders are very frequent and represent a particularly complex disease (19,20). The so-called renal osteodystrophy is mainly (but not only) associated with abnormalities in bone turnover (20). Bone biopsy is the gold standard, for example, to make the distinction between low-bone turnover (or adynamic bone disease) and high-bone turnover (or osteitis fibrosa), but this technique is cumbersome, costly and painful. Here again, the role of the laboratory is fundamental with the measurement of parathyroid hormone (PTH) and bone biomarkers (21). Cavalier reviewed which biomarkers are the most useful in the context of CKD and, still more, how they must be interpreted.

The present special issue of *Journal of Laboratory and Precision Medicine (JLPM)* underlines, if needed, the essential links between specialists in clinical chemistry and nephrologists.

### Acknowledgements

None.

### References

1. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* 2013;3:1-150.
2. KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl* 2012;2:1-138.
3. Delanaye P, Cavalier E, Pottel H. Serum Creatinine: Not So Simple! *Nephron* 2017;136:302-8.
4. Delanaye P, Cavalier E, Cristol JP, et al. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate. *J Nephrol* 2014;27:467-75.
5. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem*

- 1992;38:1933-53.
6. Boutten A, Bargnoux AS, Carlier MC, et al. Enzymatic but not compensated Jaffe methods reach the desirable specifications of NKDEP at normal levels of creatinine. Results of the French multicentric evaluation. *Clin Chim Acta* 2013;419:132-5.
  7. Kuster N, Cristol JP, Cavalier E, et al. Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. *Clin Chim Acta* 2014;428:89-95.
  8. Séronie-Vivien S, Delanaye P, Piéroni L, et al. Cystatin C: current position and future prospects. *Clin Chem Lab Med* 2008;46:1664-86.
  9. Pottel H, Delanaye P, Schaeffner E, et al. Estimating Glomerular Filtration Rate for the Full Age Spectrum from Serum creatinine and cystatin C. *Nephrol Dial Transplant* 2017;32:497-507.
  10. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012;367:20-9.
  11. Pottel H, Schaeffner E, Ebert N. Evaluating the diagnostic value of rescaled  $\beta$ -trace protein in combination with serum creatinine and serum cystatin C in older adults. *Clin Chim Acta* 2018;480:206-13.
  12. Filler G, Kusserow C, Lopes L, et al. Beta-trace protein as a marker of GFR--history, indications, and future research. *Clin Biochem* 2014;47:1188-94.
  13. Coresh J, Inker LA, Sang Y et al. Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. *Nephrol Dial Transplant* 2018. [Epub ahead of print].
  14. Delanaye P, Pottel H, Botev R, et al. Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation? *Nephrol Dial Transplant* 2013;28:1396-403.
  15. Delanaye P, Melsom T, Ebert N, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol? *Clin Kidney J* 2016;9:700-4.
  16. Delanaye P, Ebert N, Melsom T, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol ? *Clin Kidney J* 2016;9:682-99.
  17. Gaspari F, Thakar S, Carrara F, et al. Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. *Nephron* 2018;140:1-8.
  18. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. *J Am Soc.Nephrol* 2009;20:164-71.
  19. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006;69:1945-53.
  20. Moorthi RN, Moe SM. Recent advances in the noninvasive diagnosis of renal osteodystrophy. *Kidney Int* 2013;84:886-94.
  21. Delanaye P, Souberbielle JC, Lafage-Proust MH, et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. *Nephrol Dial Transplant* 2014;29:997-1004.



Pierre Delanaye

**Pierre Delanaye**

*Department of Nephrology-Dialysis-Transplantation, University of Liège (ULg CHU), CHU Sart Tilman, Liège, Belgium*

*(Email: pierre\_delanaye@yahoo.fr)*

doi: 10.21037/jlpm.2018.09.09

*Conflicts of Interest:* The author has no conflicts of interest to declare.

**View this article at:** <http://dx.doi.org/10.21037/jlpm.2018.09.09>

doi: 10.21037/jlpm.2018.09.09

**Cite this article as:** Delanaye P. Nephrology and clinical chemistry: friends for life! J Lab Precis Med 2018;3:83.